Logo Unión Europea

Axitinib impurity D (EP)

Axitinib impurity D (EP)

GA01204 - 95%


In stock
Delivery: 3 to 5 working days
Others quantities on request

Specifications

  • Description

    GA01204

    Axitinib is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models[3] and has shown partial responses in clinical trials with renal cell carcinoma (RCC)[4] and several other tumour types.

    We have successfully synthesized standards of the Axitinib. This will be of interest to pharmaceutical companies and analytical labs.

  • Additional information
    Packing Unit

    25 mg, 50 mg